As the anti-aging market continues to expand and synthetic biology continues to develop, the recombinant collagen market has risen and has gradually become a leader in the anti-aging field.
Competition in the billions of recombinant collagen market is fierce. How to detonate information and maintain cognitive advantages in the minds of the target population is crucial for Weimi® to break through the competition. As the leader in the recombinant humanized collagen track, Jinbo Biotech will take the lead in the beginning of 2024, landing on Focus Media and launching the "Weiyi Dollar Plan", linking more than 40 leading institutions across the country, in Beijing, Shanghai, Shenzhen, The 10 major cities of Suzhou, Guangzhou, Chongqing, Chengdu, Hangzhou, Taiyuan and Xiamen have started offline promotion. With the help of Focus Media’s precise connection using scene as algorithm, it can capture the minds of mainstream users and realize the symbiosis of long-termism and value between brands and institutions. In the competition The increasingly fierce recombinant humanized collagen market has found a new breaking point.
Forge ahead with technology first, build strong technological strength and build a brand moat
Jinbo Biotechnology is a company that applies cutting-edge technologies such as structural biology and protein rational design. Focusing on the fields of new life and health materials and anti-virus, it systematically engages in basic research such as functional protein structure analysis and function discovery, and uses methods such as synthetic biology to achieve functions. It is a high-tech enterprise specializing in the large-scale production of protein, and is also a national-level "specialized, special and innovative" small giant enterprise. The main business is the R&D, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.
On July 20, 2023, Jinbo Biotech was listed on the Beijing Stock Exchange, becoming the first recombinant humanized collagen stock in China. Public data shows that China's recombinant collagen market size is expected to reach 108.3 billion yuan by 2027. In the fierce competition in the billions of recombinant collagen market, as the only injectable type A humanized collagen product at present, the industry's leading brand Weimei® has its irreplaceable advantages. Through Jinbo Biotech's unique core functional area screening system, the highly active area of human collagen was selected, and the world's first atomic structure analysis of the amino acid sequence was carried out. Highly active areas that can form a triple helix were selected from 10,000 sequences and prepared by genetic engineering. , a collagen product that does not contain any modifications and is 100% identical to human natural collagen sequence.
"Recombinant collagen" has gone through the period of barbaric growth and has gradually entered the stage of quality improvement. Facing a clearer and more standardized market environment, powerful brands like Weimei® will surely usher in a new round of development opportunities. .
Backed by Jinbo Biotech's strong scientific research strength and technological advantages, Weimei® has successfully established a brand moat and successfully guided the industry's operating standards, becoming the leading brand in the recombinant collagen market.
Join hands with Focus to accelerate the new practice of leading the way to disrupt the collagen industry
This time, Jinbo Biotech landed in Focus, igniting the mainstream crowd and strongly establishing the recognition of "Weimei® Humanized Collagen Leader", creating barrier-free conditions for the brand's subsequent climb and growth.
As a rare media with active viewing and detonation capabilities, Focus Media uses "elevator scenes" as the output carrier of daily life solutions, thereby achieving precise, stable and continuous connections between brands and users. With Focus Elevator TV, Focus Media Elevator posters, Focus Cinema, etc. serve as "scenario media" to empower brand growth.
From Made in China to Smart Made in China, Jinbo Biotech’s leading position in recombinant humanized collagen technology is obvious to all. This time, it has linked up with high-quality institutions across the country to continue to output positive value through new communication forms, new marketing ideas, and new contact paths. Promoting changes in thinking also allows more people to see Chinese science and technology and feel the power of a great power. As its reputation and professionalism take root in the minds of consumers, Jinbo Biotechnology will continue to lead the industry, go deeper and deeper in the field of recombinant collagen, and move towards a higher level.